Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) (PRISM II)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
OptumInsight Life Sciences
Information provided by (Responsible Party):
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01799941
First received: February 25, 2013
Last updated: February 26, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)